A diagnosis of an autism spectrum disorders is usually associated with substantial lifetime costs to an individual, their family and the community. However, there remains an elusive factor in any cost-benefit analysis of ASD diagnosis, namely the cost of not obtaining a diagnosis. Given the infeasibility of estimating the costs of a population that, by its nature, is inaccessible, the current study compares expenses between families whose children received a formal ASD diagnosis immediately upon suspecting developmental atypicality and seeking advice, with families that experienced a delay between first suspicion and formal diagnosis.
A register based questionnaire study covering all families with a child with ASD in Western Australia.
Families with one or more children diagnosed with an ASD, totalling 521 children diagnosed with an ASD; 317 records were able to be included in the final analysis.
The median family cost of ASD was estimated to be AUD $34,900 per annum with almost 90% of the sum ($29,200) due to loss of income from employment. For each additional symptom reported, approximately $1,400 cost for the family per annum was added. While there was little direct influence on costs associated with a delay in the diagnosis, the delay was associated with a modest increase in the number of ASD symptoms, indirectly impacting the cost of ASD.
A delay in diagnosis was associated with an indirect increased financial burden to families. Early and appropriate access to early intervention is known to improve a child's long-term outcomes and reduce lifetime costs to the individual, family and society. Consequently, a per symptom dollar value may assist in allocation of individualised funding amounts for interventions rather than a nominal amount allocated to all children below a certain age, regardless of symptom presentation, as is the case in Western Australia.
Citation: Horlin C, Falkmer M, Parsons R, Albrecht MA, Falkmer T (2014) The Cost of Autism Spectrum Disorders. PLoS ONE 9(9): e106552. https://doi.org/10.1371/journal.pone.0106552
Editor: Jennifer Gladys Mulle, Emory University School Of Medicine, United States of America
Received: January 15, 2014; Accepted: August 4, 2014; Published: September 5, 2014
Copyright: © 2014 Horlin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded by the Department of Social Services (DSS), formerly the Department of Families, Housing, Community Services and Indigenous Affairs (FaHCSIA), with in-kind support of the Autism CRC, established and supported under the Australian Government's Cooperative Research Centres Program. The research was also conducted in collaboration with Disabilities Services Commission Western Australia (DSC). DSS had no active role in the design, implementation, data collection, analysis or interpretation of the study. DSC collaborated with the authors and assisted in data collection by in-kind contribution of its employee's time in some aspects of the study. Writing of the report and the decision to submit this manuscript were solely the role and responsibility of the authors. However, approval to submit this study for publication was sought from CRC Living with Autism Spectrum Disorders, DSS and DSC. All researchers are independent from both DSS and DSC and take full responsibility for the integrity of the data and the accuracy of the analyses. (DSS grant number - RES-HEA-CRD-TB-50940 http://www.dss.gov.au/)
Competing interests: The authors have declared that no competing interests exist.
A diagnosis of an Autism Spectrum Disorder (ASD) results in an estimated annual national cost to Australia of $4.5–7.2 billion  that is borne by the individuals themselves, their families, their community, and by government. Costs of autism can peak during the periods when a diagnosis is being assessed and when treatments are being administered, but many costs are ultimately on-going and constitute a life-long burden. The accurate identification of ASDs necessarily relies on assessing observable behaviours using timely, accurate, reliable and valid diagnostic procedures. At present, the “gold standard” diagnosis of autism is a lengthy and time consuming process that requires a suitably qualified multi-disciplinary team (MDT) to assess behavioural, historical and parental report information to determine a definitive diagnosis –. This is discouraging since failing to accurately identify, or prolonging the identification of, children as having ASD will delay access to apposite intervention and support services , . This issue is compounded by the possible 25 fold increase in the recent diagnosis rates of ASD in Australia , and resultant pressing demand for delivery of diagnostic services and intervention.
It is possible that the delay in treatment and support for children with ASD results in significant costs. Recently, the estimated annual adjusted costs for an adult and a child with autism have been calculated as follows (all dollar values are in AUD and rounded to the nearest dollar): where, P = production loss of the individual and family with an ASD diagnosis, SP = support costs, S = school costs, mainly addition and specialist staff, M = medical costs, and CMD = missed diagnosis. It is important to note that several assumptions are made regarding productivity costs that we do not feel fully encompass the impact of a child's diagnosis on parent employment resulting in what appears to be a very low estimate of the financial impact (e.g., time taken out from current employment for treatment visits is accounted for, but reduced employment of parents so that they can care for a child with ASD is not taken into account). Notably, estimates for the parameter CMD (missed diagnosis) have not been made and, as a result, the true benefit of a diagnosis of ASD could not be calculated. It seems plausible that an early diagnosis of autism may reduce the cost of ASD because diagnosis leads to early intervention, which results in better outcomes , , improved social behaviour , , and less reliance on specialised education support classes , . These improvements may, in turn, have knock-on benefits to families and society more broadly, as well as increased productivity for parents and the individual themselves later in life. These gains are usually accomplished when intervention is commenced very early, between the ages of 2 and 4 , .
However, the complication here is clear: those individuals remaining undiagnosed are, for that very reason, inaccessible to service providers and researchers alike. The next closest approximation that can be made for parameter CMD is therefore the difference in costs between those children identified and treated early in their development and those not identified and/or treated until later in childhood or even adolescence and adulthood. One method of estimating this cost is to identify a subgroup of children who receive a diagnosis of ASD shortly after their parents suspect their child's development is atypical, and then compare costs for these children with a subgroup of children who had their diagnosis formally confirmed much later. However, one possible offset of the cost of early diagnosis is the long-term accumulated cost of interventions and special services. Therefore, the potential added cost associated with a later diagnosis may not be substantially higher than an earlier diagnosis.
Research into the impact of receiving an early diagnosis and on a family's financial burden is limited . In Australia, state and territory governments are primarily responsible for supporting disability, including ASD, rather than the Commonwealth. However, families with a child diagnosed with an ASD receive a finite amount of Commonwealth funding up to the child's seventh birthday (the so-called “Helping Children with Autism “-funding) for the purposes of early intervention. From this point onwards, ongoing therapies and services outside of school are largely parent-funded on top of other medical and non-medical costs. Aside from the obvious cost to families of missing this early opportunity for government funding, the current study also seeks to determine whether a delayed diagnosis results in inflated costs, reduced incomes and increased financial stresses to families on a long-term basis when compared to families of individuals with a more immediate the immediate diagnosis. Thus it will be possible to estimate an accessible proxy of the parameter CMD.
Participants and Procedures
With the assistance of the Disabilities Services Commission (DSC) Western Australia, a questionnaire was distributed to families with children registered as having an ASD on their client register. Only families with diagnosed children currently under the age of 18 years were included. This decision was made in line with recommendations from the DSC based on the likelihood of correct/valid information being extractable from the register. At the time of the mail out, 3,965 children were registered with DSC from 3,723 families. Of the packages mailed out, 3,494 were sent to families with one child with ASD, 217 packages sent to families with two diagnosed children, 11 packages sent to families with three diagnosed children and one package sent to a family with four children diagnosed with ASD. Families with more than one child under 18 received one questionnaire for each child with ASD. Of the 3,723 questionnaire packs (covering 3,965 children) sent out by DSC, 192 were returned as “address unknown”. In total, 521 questionnaires were returned, resulting in a response rate of 15%.
Development of the full parent-report questionnaire was informed by anecdotal reports from clinical experts and families, the current research literature and insurance reports. Firstly, the general areas of interest were listed and all financial aspects were itemised and categorised to cover as many potential expenses that were a consequence of having a child with ASD. The questionnaire also attempted to gather and summarise information on all possible direct medical, direct non-medical and indirect costs associated with having a child with an ASD. The areas of expense addressed in the questionnaire are listed in Table 1 and specific items relevant to each area are presented in the final questionnaire in the Appendix S1 in the provided Supporting Information.
Questions were then devised to gather the information conveniently and efficiently, which would lead to clear and relevant summary reports whilst taking into account the heterogeneity of families with ASD. A pilot version of the questions and response formats were sent for comments to a number of clinical psychologists, neuropsychologists, developmental psychologists, social workers, occupational therapists, and other clinicians and service providers.
A full version of the questionnaire was then piloted on three families who have children with ASD. Based on their comments and feedback the questionnaire was adjusted to its final version (Appendix S1) and comprised a total of 73 items on demographic information, the child's diagnosis, developmental history, treatment history, education, child care and qualitative questions about the child and families' quality of life.
The final page of the questionnaire included a diagnostic checklist of DSM-IV-TR/ICD-10 items . The checklist consists of 20 symptom characteristics divided into 4 sections addressing the traditional symptom domains of;
- -Impairments in social interaction (five symptom characteristics),
- -Impairments in communication (seven symptom characteristics),
- -Restricted, repetitive and stereotyped patterns of behaviour, interest or activities (seven symptom characteristics),
- -The presence of impairments in at least one of the above before the age of three (one characteristic).
Parents were asked to indicate whether any of these characteristics currently previously applied to their child.
Questionnaire packs were prepared by the authors before being delivered to the DSC. To maintain confidentiality of the DSC's client register, all printing of cover letters and addressing of envelopes was handled by the DSC's staff and at no time did any of the researchers have access to this register. As per the DSC's records, packs were sent to the primary contact, the default for which was the diagnosed child's father. The questionnaire pack included the questionnaire itself and a reply paid return envelope. All questionnaires were de-identified and asked for no identifying information.
After a period of one month, reminders to complete the questionnaire were published online, in newspapers, DSC newsletters and on community radio. Upon receiving deidentified and completed questionnaires, a unique anonymous identifier was allocated to each questionnaire. Responses were then entered into a data file using IBM SPSS version 20 and analysed using the SAS version 9.2 statistical software.
Treatment-related travel costs.
Direct costs associated with travel for medical, therapeutic and complimentary/alternative treatments were calculated as a function of the reported frequency of average visits per month (questions 19, 28 and 36 respectively) and distance from these services (questions 18, 27 and 35 respectively). Round trip costs were calculated based on doubling the median kilometre distance from services and the average per kilometre cost of running a small car (approximated at $0.65AUD per kilometre by the most recent Royal Automobile Club figures).
Individual cost estimates were calculated for medical visits relating to a child's ASD diagnosis, therapeutic visits relating to an ASD diagnosis and complimentary/alternative visits undertaken as part of ASD treatment. These were summed to create a monthly cumulative total, which was then adjusted to create an annual estimate of treatment related travel costs according to the following formula: where V equals the number of visits per month, D equals the distance in km to the service. ‘Medical’, ‘Therapy’ and ‘Comp’ refer to medical professional services, other therapeutic services and complementary and alternative services respectively.
Out of pocket treatment costs.
The reported annual out-of-pocket costs to families in relation to ASD- specific medical, therapeutic and complimentary/alternative treatment services (questions 22, 33 and 37) were summed to create a total direct treatment cost variable. All three questions had seven potential response options representing intervals of dollar amounts. These options were then converted to the mid-point of each interval to create a single dollar amount for analysis. These recoded variables were then summed to create a cumulative total of the out of pocket costs associated with ASD-specific medical, therapeutic and complimentary/alternative treatments.
Loss of income from employment reduction.
The productivity loss associated with having a child diagnosed with ASD was calculated based on self-reported impact of their child's diagnosis on the parent/caregiver ability to work (question 51) and, if employment status was affected, the size of this reduction as a function of hours in the average work week (question 52). Those responding to question 51 by selecting options one, two or three, as presented in Table 2, then indicated the reduction in hours in question 52. This reduction was thereafter converted to a proportion of full-time equivalent (FTE) employment. Those indicating that either one or both parents could not work at all at this time due to the needs of their ASD child were converted to an FTE reduction of 1 or 2 units, respectively. Parents indicating that their employment status was unaffected were coded as 0. This variable was then multiplied with the median full-time income for 2010–2011 as reported by the Australian Taxation Office (the latest figures made available), which was $48, 864.
Cumulative cost of having a child diagnosed with ASD.
To create a single estimate of direct and indirect expenses to each family that were specifically related to having a child diagnosed with ASD, the costs associated with treatment-related travel, out-of-pocket treatment expenses and loss of income/productivity were summed.
‘Immediate’ versus ‘delayed’ diagnosis.
A dichotomous ‘immediate’ versus ‘delayed’ diagnosis variable was created based on cross-tabulations between questions 10 (age at first suspicion of something not being quite right) and 12 (age at which a formal diagnosis was received). This variable was intended to capture the chronological difference between those receiving early or more immediate diagnosis (and presumably treatment and intervention) and a later or delayed diagnosis (often after the optimal developmental window for treatment and period at which early intervention would take place). Those children with a zero or one step chronological difference between questions 10 and 12 were coded as ‘immediate’ and those with a two or more step difference between these questions were coded as ‘delayed’. A further, stricter, division of ‘immediate’ and ‘delayed’ was also conducted by retaining only those with a zero step difference between questions 10 and 12 (‘immediate’) and those with a three or more step difference (‘delayed’). These divisions are delineated in Table 3.
Cumulative presence of ASD symptoms.
The total number of ASD symptoms was estimated by a cumulative total of the positive indications from the presence of symptoms within the four domains listed on the DSM-IV/TR-ICD-10 checklist. Positive indications were coded as one and responses in domain one to three were summed to create a total for each child. The fourth domain comprised one single developmental history question and was excluded from this total, since this characteristic was regarded as a prerequisite for receiving a diagnosis of ASD.
Analysis of non-respondents.
Six months after the initial mail-out, a random sample of 405 families registered with the DSC were contacted for a telephone follow-up. Given the confidentiality of the DSC register and the de-identified nature of the returned questionnaires, it was not known which families on the register had or had not completed the long-form questionnaire. Thus, the random sample of 405 families would include those that had completed and returned a questionnaire and those that had not. Non-respondents were then asked to answer an abbreviated form of the questionnaire over the phone. This short-form phone questionnaire consisted of twenty questions taken from the original questionnaire for the purposes of a later drop-out analysis. Those questions included in the short-form are shown in italics in Appendix S1. For the purposes of comparisons between those that did and did not respond to the long-form questionnaire that was sent out via mail, independent samples t-tests were used to compare the ages of children, chi-square tests were used to compare categorical demographic variables and Mann-Whitney U tests were conducted to compare calculated cost variables. Due to the shortened nature of the short-form questionnaire, only the out of pocket treatment costs and the loss of income from employment reduction variables could be calculated for both respondents and non-respondents. The response categories of some demographic variables (question 10 and 12 specifically) were collapsed to ensure validity of the chi-square test.
Ethical approval was obtained from the Curtin University Human Research Ethics Committee (HR 138/2012) and the internal ethical review board of the DSC in Western Australia. Questionnaire packs were sent to the DSC's clients with a cover letter from the Director General of DSC explaining the nature and purpose of the study as well as an information sheet inviting families to complete and return the questionnaire. Completed and returned questionnaires were taken as consent to participate in the study.
The characteristics of the included 521 children with ASD are presented in Table 4. Descriptive statistics for all cumulative cost estimates and the cumulative presence of ASD symptoms are presented in Table 5. An additional total cost of ASD variable for families with only one child diagnosed with ASD was calculated to express the costs of ASD without the compounding effect of having multiple children with ASD and the implications this may have to reductions in FTE employment. The cumulative ‘Cost of ASD’ variable predominantly consisted of loss of income of the parents and caregivers (89%) with ASD-related travel costs (3%) and treatment costs (8%) making smaller contributions.
The cost of ASD as a function of ‘immediate’ versus ‘delayed’ diagnosis or frequency of ASD symptoms
A regression analysis was conducted with cost of ASD as the dependent variable. Independent variables included: ‘immediate’ (coded as 1) versus ‘delayed’ (coded as 2) diagnosis, ASD symptom frequency (as continuous numeric), age of child in years, number of siblings (0, 1, 2 or 3+), number of siblings with ASD (0, 1, or 2+), combined income (in $AUD), age of diagnosis of child with autism (1 = 0–12 months, 2 = 12–24 months, 3 = 2–6 years, 4 = 6–12 years, 5 = 12–18 years) and highest education of the mother and father (1 = year 10, 2 = year 12, 3 = TAFE, 4 = Apprenticeship, 5 = some university, 6 = Bachelor degree, 7 = postgraduate degree). The residuals from the regression analysis were plotted (histogram and density plots) and followed a normal distribution. The R2 values for the two models evaluating the different criteria for immediate versus delayed diagnosis (i.e., loose and strict cut off) below were 21% and 31%, respectively, as shown in Table 6.
Regardless of whether the strict or loose definition of the ‘immediate ’versus ‘delayed’ diagnosis variable was used, neither was found to be significantly associated with the of cost of ASD. However, in both regression models, the number of ASD symptoms present was a significant predictor. In both models, costs were increased by approximately $1,400 per ASD symptom reported for the loose and strict criteria models. Models with fewer covariates were also fitted yielding similar estimates for the cost of immediate versus delayed diagnosis and the cumulative presence of ASD symptoms.
A delay in diagnosis and treatment may have an indirect effect on costs associated with ASD by increasing the number of symptoms present. In order to test this hypothesis, a mediation analysis was conducted. Firstly, it was confirmed that a delay in diagnosis was statistically significantly associated with an increased number of symptoms (number of increased symptoms associated with delay = 1.56, p = 0.001, 95% CI = 0.63, 2.49). Following this, two models were constructed and contrasted: 1) total costs were modelled as a function of delay in diagnosis alone, with the direct effect of diagnostic delay denoted as c, and 2) total costs were modelled as a function of delay in diagnosis and cumulative symptom count, with the parameter estimate for delay in diagnosis with the effect attributable to cumulative symptom count partialled out denoted c′. The final mediated effect was calculated by subtracting c′ from c (i.e., mediated effect = c – c′). To produce 95% CIs around the mediated effect, 10,000 bootstrapped samples were taken and the quantiles representing 2.5% and 97.5% of the c - c′ distribution calculated. Bootstrapping the estimate of the mediated effect has been recommended for mediation analysis because the technique offers acceptable statistical power properties, directly estimates the mediated effect, and does not rely on many of the assumptions necessary for other tests , .
The mediation analysis was supportive of this hypothesis. A statistically significant reduction in the effect associated with diagnostic delay of $2,110 (95% CI = 820, 3700) was observed when symptom count was included in the model. This was despite the delay in diagnosis not being statistically significantly associated with total cost directly (see above). The mediation analysis was repeated with all covariates included in the original model (age of child, number of siblings, number of siblings with ASD, combined income, age of ASD diagnosis, and highest education of mother and father) and a similar effect was found (mediated effect c-c′ = $1,770, 95% CI = 360, 3340).
Analysis of non-respondents
Contact was established with 267 of the 405 families who did not return a completed questionnaire, and, of these, 148 agreed to complete the short-form questionnaire. Sixty-four families had already completed the long-form questionnaire. Fifty-two families (13%) declined to participate in the phone questionnaire. Incorrect phone numbers and no answer were the main reasons for failures to contact. A complete breakdown of the telephone sample is shown in Figure 1. Two of the 148 families that agreed to participate did not have a child with ASD. From the 146 families with children with ASD that agreed to complete the short- form questionnaire, data were collated for 171 individual children.
A full representation of a random sample of families registered as having received or currently receiving service provision for the purposes of an analysis of non-respondents. From a random sample of 405 families, 146 families (totalling 171 children with ASD) agreed to participate in the telephone questionnaire
As shown in Table 7, there were few noteworthy differences between respondents and non- respondents. Demographically, respondents were slightly more likely to have a male child and to have noticed developmental atypicality earlier. Respondents also received a formal diagnosis of ASD earlier than non-respondents. Respondents reported higher treatment costs than non-respondents. However, there were no differences in reported income loss.
ASD-related costs were strongly associated with the cumulative presence of the child's symptoms. This builds upon previous research that has found that having a child with ASD is associated with significant financial strain –. The association between increased costs and ASD symptom severity suggests that effective and early interventions that result in the reduction of expressed symptoms may have a significant impact on improving a family's productivity and their resultant financial situation.
Contrary to expectations, there was no statistically significant differences in costs related to receiving the diagnosis of ASD whether soon or late after suspicion. We suggest two possible reasons for this. Firstly, given the above finding that increasing symptomatology is directly related to the cost of ASD, the more immediate identification of ASD may create a situation where improvement in outcomes and the effect on associated symptomatology measures dwarfs the influence of delay to diagnosis on the final cost of ASD. This interpretation appears to be consistent with the mediation analysis, whereby an indirect effect of diagnostic delay on costs appeared to be mediated by an association between increased symptomatology and increased diagnostic delay. Secondly, families with a child with ASD may adapt their work-family balance regardless of whether the child has a diagnosis or not. This is reflected by the finding that the largest cost reported by parents was a loss of income from reduced working hours. This is consistent with a previous report stating that a loss of approximately 14% of family income is often the consequence of having a child with ASD , equalling $7,200 (based on the median income and average exchange rate of 2008). The results from the present study suggest a substantially higher (29%) loss of combined household income.
From a family and societal perspective, support that allows family members to work may more effectively assist families with children with ASD by lessening the financial burden and improving well-being of all family members. Furthermore, the long-term consequence of high costs associated with having a child who has a diagnosis of ASD is not well researched. A study reporting on the distribution of societal costs of ASD distributed throughout the lifespan estimated that fathers of children with moderate to severe autism were unemployed 20% of a full time equivalent , whereas 60% of mothers were unemployed and 30% worked part time of a full time equivalent . If these estimates are indeed accurate, the family income may therefore be severely impacted through the lifespan as a result of having a child with ASD . The largest direct life time cost is to provide care for adults with ASD , . Consequently, parents of adults with ASD may face an even larger financial strain when having to provide services for their adult children whilst having had less opportunity to save or accumulate superannuation funds due to reduced possibilities to work full time .
There are several limitations to the cost analysis presented here: 1) The return rate of 15% observed in the present study is quite poor in comparison to similar studies. This may be because client details registered with the DSC are maintained sporadically and a number of records contained incomplete or inaccurate entries. Furthermore, distributed questionnaires were addressed only to the fathers of the registered child for some families due to a DSC database error. Given reports of higher than normal divorce rates in families with children with ASD , this may be another reason for a lower than usual return rate reflected by the higher than expected number of respondents reporting being in two-parent households compared to non-respondents. 2) There are multiple reasons why a child might not be diagnosed until later in development, giving rise to a number of caveats with respect to the ‘delayed’ diagnostic group. For example, some of those diagnosed later in development may present with symptomatology that is either more complex or reduced in severity compared to those children with evident and more severe symptoms from an early age. However, this influence appeared to be relatively small as the effect of the variable “Age of diagnosis” was not a statistically significant contributor to cost, or may be reflected more by the cumulative presence of ASD symptomatology measure. 3) Requesting estimates of current costs may not be representative of historical costs as current expenses are dependent on the child's stage of development, time since diagnosis, and current stage of treatment or intervention. However, one aspect for which our estimates are robust is their specification of only ASD-related expenses for medical, behavioural or complimentary/alternative therapies. 4) In contrast to most parents that had reduced their hours due to the needs of their child with ASD, a small number of parents were seeking more work due to the expenses of having a child with ASD. This is not often considered when calculating the costs and productivity losses associated with a diagnosis of ASD. 5) A number of parents reported low treatment costs because they had exhausted all funded avenues and could not afford to independently fund treatment for their children. 5) Lastly, the present study does not address all aspects of how an immediate or delayed diagnosis may impact families and their financial situation. The processes that parents undergo in order to access a proficient diagnosis are reported as being extremely stressful  and may result in health related consequences difficult to estimate in any cost benefit analysis . Consequently, health related consequences and costs for family members and society in relation to early/late diagnosis may warrant further scrutinising.
The median family cost of ASD was estimated to be AUD $34,900 per annum (IQR $20,700 - $51,700; based on median income from wages), with almost 90% of the sum ($29,200) due to loss of income from employment. While there was no statistically significant direct effect on the cost depending on the timeliness of the diagnosis (immediate versus delayed) the cumulative presence of ASD symptoms had a significant impact on the costs and a delay in diagnosis could indirectly increase costs by neglecting symptoms that may respond to more immediate intervention. For each additional symptom reported, a $1,400 cost for the family per annum was added. These findings take on a great deal of significance when considered within a regional context as funding amounts vary across states and countries. The financial burden of families of children with ASD is correlated with the existing societal financial safety net . In an Australian context, families may miss out on the most widely available financial support for early intervention if the diagnosis is received after the age of six . If the family is expected to carry a substantial share of the cost needed to support the development of children with ASD, this may have detrimental consequences for the wellbeing of the child with ASD, as well as for other family members, especially for low income families that may not seek services at all for financial reasons .
The complete questionnaire. Those questions included in the short form are shown in italics.
Aoife McNally, Kirsty Oehlers, Mandy Richards, Geoff Cole, Susan Peden, staff at Disabilities Services Commission, Caitlin Axford, Fiona Choi, Helen Weldergergish, Rachel Owens, Rex Parsons, Stephen Lawrie, Gal Rose, Tim Parkin and the AIM employment AAWA.
Authorship statement& transparency declaration
The final manuscript has been seen and approved by all authors and they have taken due care to ensure the integrity of the work. The work is original and has not been published elsewhere and is currently not under consideration by another journal. All authors have had full access to the data, analysis and writing and editing has jointly been done.
The lead author affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.
Conceived and designed the experiments: CH MF MA TF. Performed the experiments: CH MF. Analyzed the data: CH RP MA TF. Wrote the paper: CH MF RP MA TF.
- 1. Consulting SE (2007) Economic Costs of ASD in Australia. Synergies Economic Consulting.
- 2. Le Couteur A, Haden G, Hammal D, McComachie H (2008) Diagnosing Autism Spectrum Disorders in pre-school children using two standardised assessment instruments: The ADI-R and the ADOS. Journal of Autism and Developmental Disorders 38: 362–372.
- 3. Woolfenden S, Sarkozy V, Ridley G, Williams K (2012) A systematic review of the diagnostic stability of Autism Spectrum Disorder. Research in Autism Spectrum Disorders 6: 345–354.
- 4. Shattuck PT, Grosse SD (2007) Issues related to the diagnosis and treatment of autism spectrum disorders. Mental Retardation and Developmental Disabilities Research Reviews 13: 129–135.
- 5. Sikora D, Hall T, Hartley S, Gerrard-Morris A, Cagle S (2008) Does Parent Report of Behavior Differ Across ADOS-G Classifications: Analysis of Scores from the CBCL and GARS. Journal of Autism and Developmental Disorders 38: 440–448.
- 6. South M, Williams B, McMahon W, Owley T, Filipek P, et al. (2002) Utility of the Gilliam Autism Rating Scale in Research and Clinical Populations. Journal of Autism and Developmental Disorders 32: 593–599.
- 7. McEachin JJ, Smith T, Lovaas OI (1993) Long-term outcome for children with autism who received early intensive behavioral treatment. American Journal on Mental Retardation 97: 359–372.
- 8. Rogers S (1996) Brief report: Early intervention in autism. Journal of Autism and Developmental Disorders 26: 243–246.
- 9. Lovaas OI (1987) Behavioral treatment and normal educational and intellectual functioning in young autistic children. Journal of Consulting and Clinical Psychology 55: 3–9.
- 10. Remington B, Hastings RP, Kovshoff H, degli Espinosa F, Jahr E, et al. (2007) Early Intensive Behavioral Intervention: Outcomes for Children With Autism and Their Parents After Two Years. American Journal on Mental Retardation 112: 418–438.
- 11. Harris SL, Handleman JS (2000) Age and IQ at Intake as Predictors of Placement for Young Children with Autism: A Four- to Six-Year Follow-Up. Journal of Autism and Developmental Disorders 30: 137–142.
- 12. Fenske EC, Zalenski S, Krantz PJ, McClannahan LE (1985) Age at intervention and treatment outcome for autistic children in a comprehensive intervention program. Analysis and Intervention in Developmental Disabilities 5: 49–58.
- 13. Matson JL, Wilkins J, Boisjoli JA, Smith KR (2008) The validity of the autism spectrum disorders-diagnosis for intellectually disabled adults (ASD-DA). Research in Developmental Disabilities 29: 537–546.
- 14. Hayes AF (2009) Beyond Baron and Kenny: Statistical mediation analysis in the new millennium. Communication Monographs 76: 408–420.
- 15. MacKinnon DP, Fairchild AJ, Fritz MS (2007) Mediation analysis. Annual Review of Psychology 58: 593.
- 16. Montes G, Halterman JS (2008) Association of Childhood Autism Spectrum Disorders and Loss of Family Income. Pediatrics 121: e821–e826.
- 17. Parish SL, Thomas KC, Rose R, Kilany M, Shattuck PT (2012) State Medicaid Spending and Financial Burden of Families Raising Children with Autism. Intellectual and Developmental Disabilities 50: 441–451.
- 18. Phelps KW, Hodgson JL, McCammon SL, Lamson AL (2009) Caring for an individual with autism disorder: A qualitative analysis*. Journal of Intellectual and Developmental Disability 34: 27–35.
- 19. Sharpe D, Baker D (2007) Financial Issues Associated with Having a Child with Autism. Journal of Family and Economic Issues 28: 247–264.
- 20. Ganz ML (2007) THe lifetime distribution of the incremental societal costs of autism. Archives of Pediatrics & Adolescent Medicine 161: 343–349.
- 21. Ganz M (2006) The Costs of Autism. Understanding Autism: CRC Press. pp. 475–502.
- 22. Hartley SL, Barker ET, Seltzer MM, Floyd F, Greenberg J, et al. (2010) The Relative Risk and Timing of Divorce in Families of Children with an Autism Spectrum Disorder. Journal of Family Psychology 24: 449–457.
- 23. Keenan M, Dillenburger K, Doherty A, Byrne T, Gallagher S (2010) The Experiences of Parents During Diagnosis and Forward Planning for Children with Autism Spectrum Disorder. Journal of Applied Research in Intellectual Disabilities 23: 390–397.
- 24. Australian Government (2013) Helping Children with Autism. Department of Families, Housing, Community Services and Indigenous Affairs